Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 12,734 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Clear all
Completed Phase 3 Interventional

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

NCT02110368
View directory record Official record
Conditions
Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions
Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glans Size in Hypospadias Compared to Normal

NCT03593720
View directory record Official record
Conditions
Hypospadias, Surgery Non Hypospadias
Interventions
Measurement in Office, Measurement in OR
Procedure
Lead sponsor
Albany Medical College
Other
Eligibility
Male only
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients

NCT00472082
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
efalizumab
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients

NCT02019524
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
E39 peptide vaccine, E39 vaccine then J65 vaccine, J65 vaccine then E39 vaccine
Biological
Lead sponsor
COL George Peoples, MD, FACS
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting No phase listed Observational

Partners Calciphylaxis Biobank

NCT03032835
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy, End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer

NCT02440308
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
68Ga-DOTA-Bombesin, Magnetic Resonance Imaging (MRI) scan, Positron Emission Tomography (PET) scan
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 21, 2026, 6:40 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

NCT06027268
View directory record Official record
Conditions
Metastatic Triple-Negative Breast Cancer
Interventions
Trilaciclib, Pembrolizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Phase 2 Interventional Results available

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

NCT04544410
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Tildacerfont/Placebo
Drug
Lead sponsor
Spruce Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Prehabilitation in High-risk Oncologic Surgery

NCT07638410
View directory record Official record
Conditions
Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal Surgery Complications
Interventions
Multidisciplinary Prehabilitation Program
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Not applicable Interventional

House Calls and Peer Mentorship

NCT03354910
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
House Call, Peer Mentorship
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 21, 2026, 6:40 PM EDT
Terminated Phase 2 Interventional

Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080782
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Celecoxib, Doxorubicin Hydrochloride, Strontium chloride Sr 89
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational

Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community

NCT00339482
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years to 99 Years
Enrollment
12,647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1976
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

NCT04335682
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer, Castrate Resistant Prostate Cancer, Hormone Sensitive Prostate Cancer, Non-metastatic Prostate Cancer
Interventions
Darolutamide, Enzalutamide
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Fairway, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational Results available

Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients

NCT00932659
View directory record Official record
Conditions
Arrhythmias, Cardiac
Interventions
continuous cardiac monitoring device (REVEAL, Medtronic)
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

NCT06394869
View directory record Official record
Conditions
Hematuria - Cause Not Known
Interventions
Cxbladder Triage Plus
Diagnostic Test
Lead sponsor
Pacific Edge Limited
Industry
Eligibility
18 Years to 88 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Active, not recruiting Phase 1 Interventional

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

NCT04794699
View directory record Official record
Conditions
Solid Tumor
Interventions
IDE397, Sacituzumab govitecan
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Duarte, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT07090499
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
PF-08046876, Pembrolizumab, Cisplatin, Carboplatin
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Addressing Health Literacy With a Tailored Survivorship Care Plan

NCT06674863
View directory record Official record
Conditions
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Educational Intervention, Interview, Questionnaire Administration, Supportive Care
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Not applicable Interventional

A Behavioral Health Intervention Using Digital Technology in Radiation Therapy for Prostate Cancer Patients

NCT04946214
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity
Interventions
Smart Water Bottle
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 21, 2026, 6:40 PM EDT
Completed No phase listed Observational

Systolic Pressure Intervention Trial Factors Affecting Factors Affecting Atherosclerosis Study

NCT01475747
View directory record Official record
Conditions
Hypertension, Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
12
States / cities
Palo Alto, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 21, 2026, 6:40 PM EDT
Enrolling by invitation Not applicable Interventional

ECHO for Diabetes and Multiple Chronic Conditions Study

NCT06451458
View directory record Official record
Conditions
Diabetes Mellitus, Chronic Disease
Interventions
ECHO program for DMMC, Usual care
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Active, not recruiting Not applicable Interventional

How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding

NCT07125326
View directory record Official record
Conditions
Urinary Retention, Urinary Tract Infection (Diagnosis), Postpartum Acute Urinary Retention, Postpartum Care, Voiding Dysfunction
Interventions
Intermittent catheterization, Continuous catheterization
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

NCT01621178
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Disease
Interventions
Dulaglutide, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Montgomery, Alabama • Azusa, California • Granada Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 21, 2026, 6:40 PM EDT
Completed Not applicable Interventional

An Evaluation of a Gender Specific Insole to Provide Relief From Knee Pain Due to Osteoarthritis or General Anterior Knee Pain in Male Subjects When Used in Foot Wear Over a Period of Four Weeks

NCT03556787
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
BPI 1000013 (Dr Scholls Insole)
Device
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Calabasas, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Oct 21, 2026, 6:40 PM EDT